# Tirzepatide trial groups aren't personal targets.

Tirzepatide is the ingredient in Zepbound. Its study results can make “more” sound like the obvious answer. But a group average can't tell you which amount is worthwhile for one person. The side effects have a say in that, too.

## Higher groups lost more on average

mass

The [weight trial called SURMOUNT-1](https://pubmed.ncbi.nlm.nih.gov/35658024/) enrolled adults with obesity, or overweight with a weight-related complication, without diabetes. Researchers compared different weekly amounts of injected tirzepatide with placebo, a treatment without the drug.

Over 72 weeks, higher tirzepatide groups lost more weight on average. That's an average, not a personal target. It doesn't identify the best amount for you or give a sequence to follow.

Reading limit: The group with the largest average loss cannot choose treatment for you.

## Two headlines cannot pick a winner

people

The [semaglutide STEP 1 trial](https://pubmed.ncbi.nlm.nih.gov/33567185/) also measured weight change. It enrolled adults with obesity, or overweight with a weight-related condition, without diabetes. That sounds close to SURMOUNT-1, but these were separate trials with separate participants.

Putting their headlines side by side doesn't turn them into a direct comparison. It also doesn't give us a milligram-for-milligram exchange rate. Neither trial tested how to switch from one medicine to the other. That question still needs an individual medical assessment.

Reading limit: Separate trials cannot establish which medicine is best for an individual.

## The stomach gets a vote

change

Nausea, diarrhea and vomiting were common in [the SURMOUNT-1 trial](https://pubmed.ncbi.nlm.nih.gov/35658024/), especially while study amounts were increasing. “Worked on average” can still mean an uncomfortable experience.

A [review combining safety studies](https://pubmed.ncbi.nlm.nih.gov/37908750/) examined gallbladder or bile-duct disease and pancreatitis, inflammation of the pancreas. Its pancreatitis estimate was too uncertain to rule out an increase in risk. The [Zepbound label warns about both gallbladder problems and pancreatitis](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b). A study can leave a question open without supplying an all-clear.

Reading limit: An uncertain risk finding is not proof that the risk is absent.

## The label still matters

limits

The [Zepbound label carries its strongest warning about thyroid tumors seen in rats](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b). The human risk is unknown. It rules out use with a personal or family history of medullary thyroid cancer, a rare thyroid cancer, or MEN 2, a rare inherited condition.

FDA-approved tirzepatide medicines exist. [Compounded versions are not FDA-approved](https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers). A licensed U.S. clinician can discuss suitability, side effects and monitoring. Those questions give the amount meaning; the biggest number in a trial table can't answer them for you.

Reading limit: The medical decision includes health history and tolerability as well as possible benefit.

---

Every amount, in company.

Dose Peptide is a guide to reading an amount in context, not a clinic, a pharmacy or a seller.

© 2026 Dose Peptide